Most Read Articles
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Jairia Dela Cruz, 4 days ago
A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.
Pearl Toh, 14 Feb 2020
Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).
Stephen Padilla, 3 days ago
Use of proton pump inhibitors (PPIs) among patients with Crohn’s disease (CD) could increase their risk of interval flare and is associated with nonremission status, according to a study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).

Ustekinumab induces, maintains clinical remission in patients with Crohn's disease

Stephen Padilla
27 Jan 2020

Use of ustekinumab results in clinical remission, with successful maintenance until week 48, and improves laboratory biomarkers of disease activity in patients with moderate-to-severe Crohn’s disease (CD) who are refractory to antitumour necrosis factor (anti-TNF) therapy, according to a real-world study in Brazil presented at the 2019 Advances in Inflammatory Bowel Disease (AIBD) Annual Meeting.

Ustekinumab was given to 161 patients (mean age, 38.2 years; 55.3 percent female; disease duration, 10.3 years) during the study period. Of these, 58.4 percent had previous surgeries, 46.6 percent had perianal disease, 55.5 percent had anaemia, and 16.2 percent were smokers.

Most of the patients received 90-mg ustekinumab every 8 weeks (97.4 percent) during maintenance and had prior exposure to biological therapy (85.7 percent). Forty-four patients were previously exposed to one biologic, 78 to two biologics and 16 to three biologics. [AIBD 2019, abstract P065]

At baseline, 38.5 percent of patients currently or previously presented extra intestinal manifestations, with mean Harvey-Bradshaw index (HBI) of 10.1 and mean C-reactive protein (CRP) of 21.3 mg/L.

Of the patients, 76.9 percent achieved clinical response and 38.9 percent achieved clinical remission at week 8. Clinical remission was maintained in 53.1 percent at week 16, in 53.9 percent at week 24 and in 62.5 percent at week 48. CRP decreased to 14.4 mg/L at week 8 and further to 7.7 mg/L at week 48.

About one in four patients (28.6 percent) experienced adverse events. Treatment with ustekinumab was stopped in 24 patients: 13 due to surgery and/or lack of response, three due to pregnancy, seven due to lack of access and one due to depression. No new safety signals were found.

“Both ustekinumab induction and maintenance regimens until week 48 were overall well tolerated,” the researchers said. “These results support a favourable safety and efficacy profile.”

In addition, statistical analysis revealed that better outcomes were associated with inflammatory behaviour, naïve or prior exposure to one biological therapy, and disease duration <2 years.

In this retrospective chart review and prospective study, the researchers examined patients with moderate-to-severe CD initiating on ustekinumab (intravenous infusions followed by scheduled subcutaneous injections) from 11 IBD referral centres between November 2017 and April 2019.

Clinical response and remission (based on HBI) and CRP levels were assessed. Clinical remission was evaluated at weeks 0, 8, 16, 24 and 48, and CRP at weeks 0, 8 and 48. Statistical analysis was also conducted, with the data presented as observed.

“Ustekinumab is a fully human monoclonal antibody against IL-12/23 approved in Brazil for the treatment of moderate-to-severe CD in November 2017,” according to the researchers. “Ustekinumab has demonstrated its efficacy in induction and maintenance therapy for patients with CD.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 12 Feb 2020

Children with inflammatory bowel disease (IBD) do not appear to have an elevated risk of lymphoma following treatment with anti-tumour necrosis factor (TNF) agents, according to a study presented at the recent Crohn’s and Colitis Congress 2020.

Jairia Dela Cruz, 4 days ago
A diet low in fat and high in fibre seems well tolerated in patients with ulcerative colitis, not contributing to increased inflammation while significantly increasing populations of Faecalibacterium prausnitzii, according to a study presented at the 2020 Crohn's & Colitis Congress.
Pearl Toh, 14 Feb 2020
Donor selection for faecal microbiota transplant (FMT) can make a difference to maintenance of long-term remission in patients with ulcerative colitis (UC), reveals a study presented at the 2020 Crohn's & Colitis Congress (CCC).
Stephen Padilla, 3 days ago
Use of proton pump inhibitors (PPIs) among patients with Crohn’s disease (CD) could increase their risk of interval flare and is associated with nonremission status, according to a study presented at the 2020 Crohn’s and Colitis Congress (CCC 2020).